ArticleBMC pulmonary medicine2026
Anti-cyclic citrullinated peptide antibody in bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated interstitial lung disease (RA-ILD) share several risk factors, genetic backgrounds, and morphological features, including the usual interstitial pneumonia pattern on computed tomography and histopathology. Anti-cyclic citrullinated peptide antibodies (ACPAs) are RA-related autoantibodies that are associated with RA-ILD. ACPA production can be induced in the lungs of patients with IPF.
methodsForty-four patients with IPF and 10 patients with RA-ILD underwent bronchoalveolar lavage fluid (BALF) collection. The concentrations of IgG ACPAs in the BALF were measured and corrected for total IgG levels. The relationships between corrected BALF ACPA levels and clinical features were investigated.
resultsThe proportion of ACPAs (ACPA-IgG level adjusted by total IgG level) in the BALF was significantly lower in patients with IPF than in those with RA-ILD (1222 ± 1424 U/mg vs. 9058 ± 15159 U/mg, p < 0.01). Compared with the group with low ACPA proportions (n = 29), the IPF group with high ACPA proportions (n = 15) in the BALF was younger (65.2 ± 9.4 years vs. 70.9 ± 6.8 years, p = 0.03) and had more females (6 out of 15 (40%) vs. 2 out of 29 (7%), p = 0.01). Additionally, the IPF patients with a high ACPA proportion in the BALF had significantly better outcomes than those with a low ACPA proportion did (median overall survival time: 92.4 months vs. 41.1 months, p = 0.04).
conclusionThe corrected BALF ACPA level might be an important biomarker for identifying IPF phenotypes with favourable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.